Bank of New York Mellon Corp decreased its stake in shares of STAAR Surgical Company (NASDAQ:STAA) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 158,863 shares of the medical instruments supplier’s stock after selling 1,323 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.39% of STAAR Surgical worth $1,716,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in STAA. Palo Alto Investors LLC lifted its holdings in STAAR Surgical by 2.6% during the 1st quarter. Palo Alto Investors LLC now owns 3,473,170 shares of the medical instruments supplier’s stock valued at $34,037,000 after buying an additional 86,925 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in STAAR Surgical by 151.1% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 113,000 shares of the medical instruments supplier’s stock valued at $1,220,000 after buying an additional 68,000 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in STAAR Surgical during the 2nd quarter valued at about $282,000. Renaissance Technologies LLC lifted its holdings in STAAR Surgical by 18.6% during the 1st quarter. Renaissance Technologies LLC now owns 144,300 shares of the medical instruments supplier’s stock valued at $1,414,000 after buying an additional 22,600 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in STAAR Surgical by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 1,272,972 shares of the medical instruments supplier’s stock valued at $12,475,000 after buying an additional 18,621 shares in the last quarter. Institutional investors own 76.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/18/staar-surgical-company-staa-shares-sold-by-bank-of-new-york-mellon-corp.html.

A number of equities research analysts recently weighed in on STAA shares. TheStreet upgraded shares of STAAR Surgical from a “d+” rating to a “c” rating in a report on Tuesday, August 15th. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price objective on shares of STAAR Surgical in a report on Sunday, October 8th. Benchmark Co. lifted their price objective on shares of STAAR Surgical from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, August 14th. Zacks Investment Research lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Friday, September 22nd. Finally, BidaskClub upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $13.33.

Shares of STAAR Surgical Company (NASDAQ:STAA) opened at 13.05 on Wednesday. The stock has a 50 day moving average of $12.26 and a 200 day moving average of $10.67. The company’s market cap is $536.46 million. STAAR Surgical Company has a 12-month low of $7.45 and a 12-month high of $13.95.

STAAR Surgical (NASDAQ:STAA) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.04. The company had revenue of $21.90 million during the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. STAAR Surgical’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.02) earnings per share. Analysts forecast that STAAR Surgical Company will post ($0.11) earnings per share for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.